• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Endocrinology

Adding antiandrogen therapy to radiation improves overall survival in recurrent prostate cancer

byNeil D'SouzaandShaidah Deghan, MSc. MD
February 2, 2017
in Endocrinology, Imaging and Intervention, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The addition of biclutamide (antiandrogen) to radiation therapy for recurrent prostate cancer improved overall survival compared to radiation alone.

2. Radiation therapy and biclutamide resulted in lower incidences of metastatic, and death from, prostate cancer.

Evidence Rating Level: 1 (Excellent)

Study Rundown: For patients with localized prostate cancer a recurrence greater than 30% has been anticipated after a radical prostatectomy. Despite salvage radiation therapy, half of these men will have disease progression. Prior studies have shown androgen deprivation or anti-androgen therapy, in addition to radiation, can prolong metastasis free survival and overall survival in men with recurrent prostate cancer. Though gonadotropin releasing hormone (GnRH) agonists are currently used more often, the long-term follow-up on therapy using anti-androgens is the subject of this trial. This double-blind, randomized controlled trial compared salvage radiation therapy and biclutamide (androgen receptor blocker) for 24 months versus radiation plus placebo in men with recurrent prostate cancer. The trial arm showed a significant improvement in overall survival at 12-years post treatment. In addition, there were lower rates of metastatic and death from prostate cancer at the 12-year mark. An important strength of this trial was the design of the research trial, large study numbers and long-term follow-up data. The main limitation is that biclutamide has been superseded by the use of GnRH agonists in current practice.

Click to read the study, published today in NEJM

Relevant Reading: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.

In-Depth [randomized controlled trial]: This was a double-blind, placebo-controlled trial completed between 1988 and 2003 involving 840 eligible men who underwent radical prostatectomy and lymphadenectomy. The participants were stage T2 (disease confined to the prostate, with positive surgical margin), or T3 (prostatic extension) with no nodal involvement. All patients had radiation therapy (64.8 Gy in 36 daily fractions, five sessions per week), and either received 24 months of biclutamide (150mg daily) or daily placebo. The primary endpoint was the rate of overall survival.

RELATED REPORTS

Plant-based diets may be associated with lower risk of aggressive prostate cancer

Wellness Check: Nutrition

#VisualAbstract: Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer

A total of 760 participants were eligible for the study. The median follow-up of surviving patients was 13 years. A total of 21 patients died from prostate cancer in the biclutamide group, compared to 46 in the placebo group. The actuarial rate of survival was 76.3% in the biclutamide group at 12 years, and 71.3% in the placebo group (HR for death, 0.77; 95% CI 0.59-0.99, p = 0.04). The 12-year incidence of death from prostate cancer in the biclutamide group was 5.8% compared to 13.4% in the placebo group (HR 0.49; 95% 0.32-0.74, p < 0.001). The cumulative incidence of distant metastases was 14.5% in the biclutamide group at 12 years compared to 23% in the placebo group (HR 0.63; 95% CI 0.46-0.87; p = 0.005). 

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: prostate cancer
Previous Post

Crizanlizumab use lowers rates of sickle cell crises

Next Post

Centrifugal-flow devices noninferior to axial-flow in advanced heart failure: The ENDURANCE trial

RelatedReports

Vegetarian diet may lower incidence of colorectal cancer
Lifestyle

Plant-based diets may be associated with lower risk of aggressive prostate cancer

January 27, 2023
Improved glycemic control in type 1 diabetics on very low-carbohydrate diets
Wellness

Wellness Check: Nutrition

January 26, 2023
#VisualAbstract: Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer
StudyGraphics

#VisualAbstract: Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer

January 4, 2023
2MM Podcast

The 2 Minute Medicine Podcast Episode 2

November 22, 2022
Next Post
Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors

Centrifugal-flow devices noninferior to axial-flow in advanced heart failure: The ENDURANCE trial

Laser therapy may be effective in patients with infantile hemangiomas

Laser therapy may be effective in patients with infantile hemangiomas

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

2 Minute Medicine Rewind February 6, 2017

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality
  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options